Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient ![](images/questionmark.png)
●  The left chart: Distribution of similarity level between NPC145217 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 5211 |
0.1-0.2 | 21454 |
0.2-0.3 | 3158 |
0.3-0.4 | 642 |
0.4-0.5 | 275 |
0.5-0.6 | 113 |
0.6-0.7 | 32 |
0.7-0.8 | 2 |
0.8-0.85 | 1 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 1 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC145217 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 1033 |
0.1-0.2 | 6384 |
0.2-0.3 | 1174 |
0.3-0.4 | 367 |
0.4-0.5 | 132 |
0.5-0.6 | 44 |
0.6-0.7 | 25 |
0.7-0.8 | 2 |
0.8-0.85 | 0 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.7059 |
Intermediate Similarity |
NPD8558 |
Approved |
0.7059 |
Intermediate Similarity |
NPD8557 |
Approved |
0.6757 |
Remote Similarity |
NPD8211 |
Approved |
0.6757 |
Remote Similarity |
NPD8210 |
Phase 3 |
0.675 |
Remote Similarity |
NPD8216 |
Approved |
0.675 |
Remote Similarity |
NPD8217 |
Clinical (unspecified phase) |
0.6744 |
Remote Similarity |
NPD398 |
Approved |
0.6744 |
Remote Similarity |
NPD400 |
Approved |
0.6744 |
Remote Similarity |
NPD399 |
Approved |
0.6667 |
Remote Similarity |
NPD8556 |
Phase 3 |
0.6486 |
Remote Similarity |
NPD9112 |
Discontinued |
0.6444 |
Remote Similarity |
NPD8624 |
Approved |
0.6341 |
Remote Similarity |
NPD8197 |
Approved |
0.6341 |
Remote Similarity |
NPD8198 |
Approved |
0.6304 |
Remote Similarity |
NPD3214 |
Discontinued |
0.619 |
Remote Similarity |
NPD8804 |
Approved |
0.619 |
Remote Similarity |
NPD8805 |
Approved |
0.6176 |
Remote Similarity |
NPD8819 |
Approved |
0.6176 |
Remote Similarity |
NPD8817 |
Phase 3 |
0.6176 |
Remote Similarity |
NPD8818 |
Approved |
0.6176 |
Remote Similarity |
NPD8820 |
Approved |
0.6176 |
Remote Similarity |
NPD8821 |
Approved |
0.6176 |
Remote Similarity |
NPD110 |
Approved |
0.6176 |
Remote Similarity |
NPD9262 |
Approved |
0.6047 |
Remote Similarity |
NPD8798 |
Approved |
0.6042 |
Remote Similarity |
NPD3215 |
Phase 1 |
0.6 |
Remote Similarity |
NPD8810 |
Clinical (unspecified phase) |
0.5957 |
Remote Similarity |
NPD9025 |
Approved |
0.5862 |
Remote Similarity |
NPD8223 |
Approved |
0.5641 |
Remote Similarity |
NPD8178 |
Approved |
0.5641
|
Remote Similarity |
NPD8177 |
Approved |